SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-046400
Filing Date
2020-10-14
Accepted
2020-10-14 16:02:40
Documents
76
Period of Report
2020-08-31

Document Format Files

Seq Description Document Type Size
1 10-Q nrix-10q_20200831.htm 10-Q 2740657
2 EX-3.1 nrix-ex31_464.htm EX-3.1 46708
3 EX-3.2 nrix-ex32_465.htm EX-3.2 290226
4 EX-31.1 nrix-ex311_9.htm EX-31.1 17828
5 EX-31.2 nrix-ex312_8.htm EX-31.2 17909
6 EX-32.1 nrix-ex321_7.htm EX-32.1 9160
7 EX-32.2 nrix-ex322_6.htm EX-32.2 9157
  Complete submission text file 0001564590-20-046400.txt   8727959

Data Files

Seq Description Document Type Size
8 XBRL INSTANCE DOCUMENT nrix-20200831.xml EX-101.INS 1642497
9 XBRL TAXONOMY EXTENSION SCHEMA nrix-20200831.xsd EX-101.SCH 57856
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nrix-20200831_cal.xml EX-101.CAL 44313
11 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrix-20200831_def.xml EX-101.DEF 191949
12 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrix-20200831_lab.xml EX-101.LAB 438446
13 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrix-20200831_pre.xml EX-101.PRE 344215
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

IRS No.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: 10-Q | Act: 34 | File No.: 001-39398 | Film No.: 201239090
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences